恒瑞医药(600276.SH)获得瑞维鲁胺片药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of Ruvelimab tablets in combination with HS-20093 for prostate cancer treatment [1] Company Summary - Ruvelimab tablets are a second-generation AR inhibitor, which have a stronger AR inhibition effect compared to first-generation AR inhibitors and do not have agonistic effects [1] - Ruvelimab tablets were approved for market launch in 2022 for the treatment of high tumor burden metastatic hormone-sensitive prostate cancer (mHSPC) patients [1]